🇪🇺 UPLIZNA in European Union

EMA authorised UPLIZNA on 25 April 2022

Marketing authorisation

EMA — authorised 25 April 2022

  • Application: EMEA/H/C/005818
  • Marketing authorisation holder: Amgen Europe B.V.
  • Local brand name: Uplizna
  • Indication: Uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (NMOSD) who are anti-aquaporin 4 immunoglobulin G (AQP4-IgG) seropositive (see section 5.1).
  • Status: approved

Read official source →

UPLIZNA in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Immunology approved in European Union

Frequently asked questions

Is UPLIZNA approved in European Union?

Yes. EMA authorised it on 25 April 2022.

Who is the marketing authorisation holder for UPLIZNA in European Union?

Amgen Europe B.V. holds the EU marketing authorisation.